Additionally, the selective cytotoxic activity of anti-CD99 CAR T cells has been observed in several preclinical cellular models of AML and solid tumors, underscoring the potential of CD99 in the design of immunotherapeutic strategies [106]. The gene discussed is CD99; the disease is acute myeloid leukemia.